Literature DB >> 6889154

Prophylaxis of otitis media in asthmatic children.

D E Schuller.   

Abstract

Seventy-two asthmatic children with recurrent otitis media were studied over a 2-year interval. They were randomly divided to receive either (1) no routine medication, (2) antihistamines whenever nasally congested, (3) daily sulfisoxazole at 500 mg twice a day, (4) pneumococcal immunization and (5) both pneumococcal vaccine and 500 mg sulfisoxazole twice daily. There was no apparent benefit in the antihistamine group. There was a mean yearly reduction in otitis media of 75% in the sulfisoxazole group, 38% in the pneumococcal vaccine group and 90% in the group treated with both agents. The latter group also had a 56% reduction in frequency of acute asthmatic attacks and a 90% decrease in hospitalizations associated with otitis media. In conclusion the use of sulfisoxazole and pneumococcal vaccine appears efficacious for management of asthmatic children with recurrent otitis media.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6889154     DOI: 10.1097/00006454-198307000-00004

Source DB:  PubMed          Journal:  Pediatr Infect Dis        ISSN: 0277-9730


  4 in total

Review 1.  What does tympanostomy tube placement in children teach us about the association between atopic conditions and otitis media?

Authors:  Young J Juhn; Chung-Il Wi
Journal:  Curr Allergy Asthma Rep       Date:  2014-07       Impact factor: 4.806

Review 2.  Respiratory Viral and Bacterial Factors That Influence Early Childhood Asthma.

Authors:  Nontobeko Mthembu; Paul Ikwegbue; Frank Brombacher; Sabelo Hadebe
Journal:  Front Allergy       Date:  2021-07-22

Review 3.  Wheeze as an adverse event in pediatric vaccine and drug randomized controlled trials: A systematic review.

Authors:  Diana Marangu; Stephanie Kovacs; Judd Walson; Jan Bonhoeffer; Justin R Ortiz; Grace John-Stewart; David J Horne
Journal:  Vaccine       Date:  2015-08-28       Impact factor: 3.641

4.  The vagal ganglia transcriptome identifies candidate therapeutics for airway hyperreactivity.

Authors:  Leah R Reznikov; David K Meyerholz; Mahmoud Abou Alaiwa; Shin-Ping Kuan; Yan-Shin J Liao; Nicholas L Bormann; Thomas B Bair; Margaret Price; David A Stoltz; Michael J Welsh
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-04-05       Impact factor: 5.464

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.